Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
6
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
16.7%
1 terminated/withdrawn out of 6 trials
83.3%
-3.2% vs industry average
17%
1 trials in Phase 3/4
60%
3 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults
Role: lead
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting
Role: lead
Evaluate Safety and Pharmacokinetics of Minocin (Minocycline) for Injection in Subjects With Renal Insufficiency
Role: lead
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Role: lead
Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers
Role: lead
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Role: lead
All 6 trials loaded